SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STDY
CUSIPN/A
Phone925-272-4999
Debt
Debt-to-Equity RatioN/A
Current Ratio8.51
Quick Ratio8.51
Price-To-Earnings
Trailing P/E Ratio-10.93
Forward P/E Ratio-6.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 million
Price / Sales116.97
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book5.22
Profitability
EPS (Most Recent Fiscal Year)($0.43)
Net Income$-23,200,000.00
Net Margins-2,177.00%
Return on Equity-68.96%
Return on Assets-36.42%
Miscellaneous
Employees26
Outstanding Shares26,630,000
Market Cap$125.80 million
Steadymed (NASDAQ:STDY) Frequently Asked Questions
What is Steadymed's stock symbol?
Steadymed trades on the NASDAQ under the ticker symbol "STDY."
How were Steadymed's earnings last quarter?
Steadymed Ltd (NASDAQ:STDY) posted its quarterly earnings data on Tuesday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.17. Steadymed had a negative net margin of 2,177.00% and a negative return on equity of 68.96%. View Steadymed's Earnings History.
When is Steadymed's next earnings date?
What is the consensus analysts' recommendation for Steadymed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steadymed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Steadymed.
Who are some of Steadymed's key competitors?
Some companies that are related to Steadymed include Five Prime Therapeutics (FPRX), Unum Therapeutics (UMRX), Rigel Pharmaceuticals (RIGL), Depomed (DEPO), Akebia Therapeutics (AKBA), Forty Seven (FTSV), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Stemline Therapeutics (STML), Aduro BioTech (ADRO), Synergy Pharmaceuticals (SGYP), Magenta Therapeutics (MGTA), Merus (MRUS), ZEALAND PHARMA/S (ZEAL) and ZIOPHARM Oncology (ZIOP).
Who are Steadymed's key executives?
Steadymed's management team includes the folowing people:
- Mr. Jonathan M. N. Rigby, Pres, CEO & Director (Age 50)
- Mr. David W. Nassif, Exec. VP & CFO (Age 64)
- Mr. Robert Zwolinski, Sr. VP of Operations
- Ms. Marylyn Rigby, Sr. Director of Investor Relations and Marketing
- Mr. Carl Hicks Jr., Editor & Chief of Bephenomental.com
When did Steadymed IPO?
(STDY) raised $56 million in an IPO on Friday, March 20th 2015. The company issued 4,300,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.
Has Steadymed been receiving favorable news coverage?
News headlines about STDY stock have trended somewhat positive recently, according to Accern. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Steadymed earned a daily sentiment score of 0.15 on Accern's scale. They also gave news stories about the company an impact score of 46.88 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Steadymed.
Who are Steadymed's major shareholders?
Steadymed's stock is owned by a number of of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (7.60%), Renaissance Technologies LLC (1.12%), SG Americas Securities LLC (0.92%) and Western Standard LLC (0.32%). Company insiders that own Steadymed stock include David W Nassif, Jonathan Rigby and Orbimed Advisors Llc. View Institutional Ownership Trends for Steadymed.
Which major investors are selling Steadymed stock?
STDY stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA. Company insiders that have sold Steadymed company stock in the last year include David W Nassif and Jonathan Rigby. View Insider Buying and Selling for Steadymed.
Which major investors are buying Steadymed stock?
How do I buy shares of Steadymed?
Shares of STDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Steadymed's stock price today?
One share of STDY stock can currently be purchased for approximately $4.70.
How big of a company is Steadymed?
Steadymed has a market capitalization of $125.80 million and generates $1.07 million in revenue each year. The company earns $-23,200,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Steadymed employs 26 workers across the globe.
How can I contact Steadymed?
Steadymed's mailing address is 5 OPPENHEIMER STREET, REHOVOT L3, 7670105. The company can be reached via phone at 925-272-4999 or via email at [email protected]
MarketBeat Community Rating for Steadymed (NASDAQ STDY)
MarketBeat's community ratings are surveys of what our community members think about Steadymed and other stocks. Vote "Outperform" if you believe STDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
